About Us

Recce Pharmaceuticals Ltd (ASX:RCE) is pioneering the development and commercialisation of a New Class of Synthetic Anti-Infectives designed to address the urgent global health threat posed by antibiotic resistant superbugs and emerging viral pathogens.

Recce’s anti-infective pipeline is comprised of broad-spectrum synthetic antibiotics, RECCE® 327 and RECCE® 435, and a synthetic anti-viral, RECCE® 529. Recce’s compounds, respectively, contain unique mechanisms of action against hypermutation on bacteria and viruses.

Recce (pronounced Re-Key) originates from the military term ‘Reconnaissance’ as a military tactic – ‘the aggressive assessment of the disposition of the enemy’. In other words, get troops behind enemy lines, identify the enemy, eliminate the threat and escape without being noticed.

We have transitioned that philosophy to anti-infectives, where our antibiotic is designed to:

  • Enter the human body
  • Bear down on the threat (deadly bacteria)
  • Eliminate that threat
  • Get out without being noticed (side effects)


Sign up for news and updates

Receive news and information direct to your inbox.